Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Thoracic 1Other solid neoplasm 1Other hematologic neoplasm 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 1Mesothelioma 1Melanoma 1Carcinoma, Non-Small-Cell Lung 1Adrenocortical Carcinoma 1

Interventions

pembrolizumab 159Carboplatin 147Cisplatin 130Pemetrexed 103Paclitaxel 89Nivolumab 71Radiotherapy 69Docetaxel 62Erlotinib Hydrochloride 58Gemcitabine 57Etoposide 44osimertinib 43Bevacizumab 43Cyclophosphamide 42durvalumab 41atezolizumab 35Cetuximab 33Radiosurgery 26130-nm albumin-bound paclitaxel 26fludarabine 23Ipilimumab 23Radiation 21Magnetic Resonance Spectroscopy 21Irinotecan 21Taxes 20Oxaliplatin 20Fluorouracil 20Gefitinib 19Everolimus 19Topotecan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × IPI-549 × Thoracic × Clear all
NCT02637531 2022-04-04

A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549

Infinity Pharmaceuticals, Inc.

Phase 1 Unknown
219 enrolled
BreastDermatologicEndocrineOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Mesothelioma, Adrenocortical Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡